Carfilzomib R&D and manufacturer

Carfilzomib (Carfilzomib) is developed and produced by Amgen, a world-renowned biopharmaceutical company. Amgen is a multinational pharmaceutical company headquartered in California, USA. Founded in 1980, it focuses on research and production in the fields of biotechnology and biopharmaceuticals.

Carfilzomib was originally developed byProteolix Corporation (predecessor), which was later acquired byAmgen in 2015. After years of research and clinical trials, this drug was finally approved by drug regulatory agencies in various countries, including the U.S. Food and Drug Administration (FDA).

Amgen is a leading biopharmaceutical and biotechnology company dedicated to developing innovative medicines, especially for the treatment of cancer and other serious diseases. Carfilzomib is an important achievement for Amgen in the treatment of multiple myeloma, providing a powerful treatment option for those living with this leukemia.

Amgen's team of professionals is dedicated to developing and producing high-quality, safe and effective medicines that meet patient needs. They have extensive experience in biopharmaceutical technologies and continually invest in scientific research to drive innovation in medicine. The development and production of carfilzomib represents Amgen's commitment in the field of oncology treatment, providing patients with better treatment options, improving their quality of life, and extending their survival.

Carfilzomib has been launched in China and is included in medical insurance. Patients can purchase it domestically at a price of around 8,000 to 9,000 yuan. Please consult the local hospital pharmacy for specific prices. In foreign countries, the original drug of carfilzomib is mainly available, and the cheaper version is the European version of the original drug, which costs around 5,000. And the medicinal ingredients and efficacy are the same as those of domestic original medicines.